These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

380 related articles for article (PubMed ID: 31803478)

  • 1. 'Reduced' HUNT model outperforms NLST and NELSON study criteria in predicting lung cancer in the Danish screening trial.
    Røe OD; Markaki M; Tsamardinos I; Lagani V; Nguyen OTD; Pedersen JH; Saghir Z; Ashraf HG
    BMJ Open Respir Res; 2019; 6(1):e000512. PubMed ID: 31803478
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-Effectiveness Analysis of Lung Cancer Screening in the United States: A Comparative Modeling Study.
    Criss SD; Cao P; Bastani M; Ten Haaf K; Chen Y; Sheehan DF; Blom EF; Toumazis I; Jeon J; de Koning HJ; Plevritis SK; Meza R; Kong CY
    Ann Intern Med; 2019 Dec; 171(11):796-804. PubMed ID: 31683314
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The HUNT lung-SNP model: genetic variants plus clinical variables improve lung cancer risk assessment over clinical models.
    Nguyen OTD; Fotopoulos I; Nøst TH; Markaki M; Lagani V; Tsamardinos I; Røe OD
    J Cancer Res Clin Oncol; 2024 Aug; 150(8):389. PubMed ID: 39129029
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Performance and Cost-Effectiveness of Computed Tomography Lung Cancer Screening Scenarios in a Population-Based Setting: A Microsimulation Modeling Analysis in Ontario, Canada.
    Ten Haaf K; Tammemägi MC; Bondy SJ; van der Aalst CM; Gu S; McGregor SE; Nicholas G; de Koning HJ; Paszat LF
    PLoS Med; 2017 Feb; 14(2):e1002225. PubMed ID: 28170394
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Selecting High-Risk Individuals for Lung Cancer Screening: A Prospective Evaluation of Existing Risk Models and Eligibility Criteria in the German EPIC Cohort.
    Li K; Hüsing A; Sookthai D; Bergmann M; Boeing H; Becker N; Kaaks R
    Cancer Prev Res (Phila); 2015 Sep; 8(9):777-85. PubMed ID: 26076698
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Economic impact of lung cancer screening in France: A modeling study].
    Gendarme S; Perrot É; Reskot F; Bhoowabul V; Fourre G; Souquet PJ; Milleron B; Couraud S
    Rev Mal Respir; 2017 Sep; 34(7):717-728. PubMed ID: 26585377
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk prediction models for selection of lung cancer screening candidates: A retrospective validation study.
    Ten Haaf K; Jeon J; Tammemägi MC; Han SS; Kong CY; Plevritis SK; Feuer EJ; de Koning HJ; Steyerberg EW; Meza R
    PLoS Med; 2017 Apr; 14(4):e1002277. PubMed ID: 28376113
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development and Validation of Risk Models to Select Ever-Smokers for CT Lung Cancer Screening.
    Katki HA; Kovalchik SA; Berg CD; Cheung LC; Chaturvedi AK
    JAMA; 2016 Jun; 315(21):2300-11. PubMed ID: 27179989
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of the lung cancer risks at which to screen ever- and never-smokers: screening rules applied to the PLCO and NLST cohorts.
    Tammemägi MC; Church TR; Hocking WG; Silvestri GA; Kvale PA; Riley TL; Commins J; Berg CD
    PLoS Med; 2014 Dec; 11(12):e1001764. PubMed ID: 25460915
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness analysis of a lung cancer screening program in the netherlands: a simulation based on NELSON and NLST study outcomes.
    Ten Berge H; Willems B; Pan X; Dvortsin E; Aerts J; Postma MJ; Prokop M; van den Heuvel MM
    J Med Econ; 2024; 27(1):1197-1211. PubMed ID: 39291295
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Early detection of lung cancer in Czech high-risk asymptomatic individuals (ELEGANCE): A study protocol.
    Lambert L; Janouskova L; Novak M; Bircakova B; Meckova Z; Votruba J; Michalek P; Burgetova A
    Medicine (Baltimore); 2021 Feb; 100(5):e23878. PubMed ID: 33592843
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Direct and indirect healthcare costs of lung cancer CT screening in Denmark: a registry study.
    Jensen MD; Siersma V; Rasmussen JF; Brodersen J
    BMJ Open; 2020 Jan; 10(1):e031768. PubMed ID: 31969362
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improving Lung Cancer Screening Selection: The HUNT Lung Cancer Risk Model for Ever-Smokers Versus the NELSON and 2021 United States Preventive Services Task Force Criteria in the Cohort of Norway: A Population-Based Prospective Study.
    Nguyen OTD; Fotopoulos I; Markaki M; Tsamardinos I; Lagani V; Røe OD
    JTO Clin Res Rep; 2024 Apr; 5(4):100660. PubMed ID: 38586302
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Participant selection for lung cancer screening by risk modelling (the Pan-Canadian Early Detection of Lung Cancer [PanCan] study): a single-arm, prospective study.
    Tammemagi MC; Schmidt H; Martel S; McWilliams A; Goffin JR; Johnston MR; Nicholas G; Tremblay A; Bhatia R; Liu G; Soghrati K; Yasufuku K; Hwang DM; Laberge F; Gingras M; Pasian S; Couture C; Mayo JR; Nasute Fauerbach PV; Atkar-Khattra S; Peacock SJ; Cressman S; Ionescu D; English JC; Finley RJ; Yee J; Puksa S; Stewart L; Tsai S; Haider E; Boylan C; Cutz JC; Manos D; Xu Z; Goss GD; Seely JM; Amjadi K; Sekhon HS; Burrowes P; MacEachern P; Urbanski S; Sin DD; Tan WC; Leighl NB; Shepherd FA; Evans WK; Tsao MS; Lam S;
    Lancet Oncol; 2017 Nov; 18(11):1523-1531. PubMed ID: 29055736
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Trade-off between benefits, harms and economic efficiency of low-dose CT lung cancer screening: a microsimulation analysis of nodule management strategies in a population-based setting.
    Treskova M; Aumann I; Golpon H; Vogel-Claussen J; Welte T; Kuhlmann A
    BMC Med; 2017 Aug; 15(1):162. PubMed ID: 28838313
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improving selection criteria for lung cancer screening. The potential role of emphysema.
    Sanchez-Salcedo P; Wilson DO; de-Torres JP; Weissfeld JL; Berto J; Campo A; Alcaide AB; Pueyo J; Bastarrika G; Seijo LM; Pajares MJ; Pio R; Montuenga LM; Zulueta JJ
    Am J Respir Crit Care Med; 2015 Apr; 191(8):924-31. PubMed ID: 25668622
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness of Lung Cancer Screening in Canada.
    Goffin JR; Flanagan WM; Miller AB; Fitzgerald NR; Memon S; Wolfson MC; Evans WK
    JAMA Oncol; 2015 Sep; 1(6):807-13. PubMed ID: 26226181
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identifying high-risk individuals for lung cancer screening: Going beyond NLST criteria.
    Fu M; Travier N; Martín-Sánchez JC; Martínez-Sánchez JM; Vidal C; Garcia M;
    PLoS One; 2018; 13(4):e0195441. PubMed ID: 29621354
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Detection of lung cancer through low-dose CT screening (NELSON): a prespecified analysis of screening test performance and interval cancers.
    Horeweg N; Scholten ET; de Jong PA; van der Aalst CM; Weenink C; Lammers JW; Nackaerts K; Vliegenthart R; ten Haaf K; Yousaf-Khan UA; Heuvelmans MA; Thunnissen E; Oudkerk M; Mali W; de Koning HJ
    Lancet Oncol; 2014 Nov; 15(12):1342-50. PubMed ID: 25282284
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Benefit-to-radiation-risk of low-dose computed tomography lung cancer screening.
    Hendrick RE; Smith RA
    Cancer; 2024 Jan; 130(2):216-223. PubMed ID: 37909872
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.